Weconducted a retrospective outcomes review ofthe charts of 22 patients with Meniere s disease who were treated with intratympanicperf usion ofmethylprednisolone and/or dexamethasone. Outcomes were determined by subjective assessment ofvertigo control and by objective changes in audiometricpure-tone average (PTA) and speech discrim ination sco re (SDS). These evaluations were made at the jirstp ostperfusion visit (short term) andat least 12 months later (long term). In the short term, 12 patients (54.5%) achievedvertigo control, 4 pa tients (18.2 %) demonstrated a greater than 10-dB improvement in PTA, and 1patient (4.5%) experienced an increase in SDS of at least 15%. In the long term, the correspo nding numbers ofpatients were 4 (18.2%) , 2 (9.1%), and 1 (4.5%) . The level of hearing ultimately deteriorated in 9 patients (40.9%). These fi ndings sugges t that intratympanic stero id pe rfus ion does not result in any long-t erm alleviation of vertigo or hearing loss. However; the short-term alleviation of vertigo seen in approximately half ofthese pa tients suggests that this treatment may be useful f or the temp orary reliefofsymptoms ofMeniere s disease.
Introduction
Meniere's disease is characterized by recurrent , spontaneous, and episodic vertigo, hearing loss , tinnitus, and aural fullness.' Becau se the disease course often fluctuates, efforts to stud y outcomes of therap y can be difficult.
Initial management with a diuretic and a low-salt diet are frequently help ful in treating Meni ere 's disea se. In the absence of any respon se to this 'regimen, sys temic cortico steroids have long been used as a second-line treatment. Steroids theoretically downregul ate the immunologic dysfunction that is believed to be an etiologic facto r in some patient s with Meni ere 's disea se. Steroids are we ll known for both their anti-inflammatory and electrol yte-alter ing effects. Inner ear steroid receptors hav e been found in anima l mod els as well as in human temporal bones.i" Inc reased cochl ear blood flow has also been propo sed as a mech an ism by which steroids act on the inner ea r. 5 • 6 Two adva ntage s of intratympanic stero id perfusion are that it obviates the systemic side effects associ ated with oral steroids and it results in the deliv ery of high concentrations of medication to the inner ear end organ. In the peril ymph , the concentration ofsteroids delivered via the intratymp anic rout e is higher than that achieved via intravenous administration; the best concentration profile has been seen with meth ylpr edni solon e." Factors that influence the passage of medication acro ss the round window membrane includ e mechanical obstru ction in the middl e ear, the integrity of the round window membrane, the degree of inflammation in the round window memb rane, and the molecul ar weight, concentration, liposolubility, and electrical charge assoc iated with specific medic ation s." No steroid ototoxicity has been demonstrated in anim al mod els."
In this article, we describ e our study of the efficacy of intratympanic steroid per fusion in patients with Meniere's disease as determined by subjective assess me nts ofvertigo and by audiometric testin g.
Patients and methods
Between Nov. I, 1998, and March 31, 2003 , 22 patients with Meniere 's disease underwent intratympan ic steroid perfu sion at the Virginia Co mmonwea lth Univ ersity Medical Center. All of these patients-I 2 wome n and 10 men, aged 24 to 78 yea rs (mean : 52)-met the diagn ostic criteria for definite Meniere's disease established by the American Academy ofOtol aryn gology-Head and Neck Surg ery (AAO -HNS).' Follow-up ranged from 12 to 47 months (mean: 24.5) .All patients had failed to respond to previous manage ment with a diure tic and a low-salt diet.
The 22 patients had recei ved between I and 5 perfusions (mean: 3) of 0.3 to 0.4 ml of steroid. Perfusions were admini stered in the office with a tuberculin syringe attached to a I-inch, 30-gauge needl e. Perfusions were de livere d under a surgical microscope by insertin g the need le into the posteroi nferio r aspect of the tympa nic memb rane. No local anesthesia was used. Patients remained in the supine pos ition wit h their head turned for 20 minu tes. While in this position, they were asked to refrai n from swa llow ing; instead, they spit their saliva into a kidney bas in. Patients returne d for reassess ment several weeks later.
Nine patient s (40 .9%) had rece ived 80 mg/ml of methylprednisolo ne,3 patie nts (13 .6%) rece ived 24 mg/ml of dexamethasone, 3 receive d 10 mg/ml of dexamethasone, and 7 (3 1.8%) received a combination of all three. The choice of medication was based on what was ava ilable at the time.
Successful control of vertigo was defined as the complete cess ation of vertigo spe lls (AA O-HNS class A). To obtain objective data, audiograms had been obtained three times: j ust prior to perfusion, at the first postperfusion visit (range: I to 10 wk; mean: 3), and at the most rece nt visit. A significant change in hearin g was defined as a 10-dB change in pure-tone average (PTA) at 0.5, 1, 2, and 4 kHz or a change in speec h discrimination score (SDS) of at least 15% . Hearing loss was defined as either mild (:::;40 dB PTA), moderate (4 1 to 60 dB) , severe (6 1 to 80 dB), or profound (>80 dB). Assessment of low-frequency (0.25, 0.5, and 1 kHz) PTA, whic h is often affecte d in Meniere's disease, was performed in the same manner.
Results
Vertigo, short term. Cessation of vertigo was reported by 12 of the 22 patien ts (54.5%) at the first visit follow ing the initial perfusion (short term).
Vertigo, long term. Cessation of vertigo at the most recent visit (long term) was reported by only 4 patients ( 18.2%). Of these 4 patients, 2 had been perfused with both 80 mg/ml of methy lpred niso lone and 24 mg/ml of dexamethasone on different occasions, I had received 80 mg/ml ofmethylprednisolone, and I had received 10 mg/ml of dexamethasone.
A udiometry, short term. At the first postperfu sion visit, 2 1 of the 22 patient s underw ent audiometry (patient 4 refused testing). Four ( 19.0%) exh ibited an improvement in PTA of at least 10 dB (table 1) . Only 1 patie nt (4.8%) exhibited an increase in SD S of at least 15% (table 2) , but this patient did not demo nstrate any impro vem ent in short-term PTA (patient 18). Three patients (14.3%) had a short-term decrease in heari ng of more than 10 dB, and 2 patient s (9.5%) had a decrease in SDS of at least 15%. Of the 3 patients who had a decrease in hearing, 1 patient's Volume 83 , Number 6 hearing loss progressed from mild to severe and 2 from moderate to seve re.
With regard to changes in shor t-term low-frequency PTA, 5 of21 patients (23.8%) had an impro vement of at least 10 dB and 5 had a deterioration (table 3) . Of those with deterior ated hearin g, I patient had mild hearing loss, 2 progressed from mild to moderate hearing loss, 1 from moderate to severe, and 1 from moderate to profound. In both patients who progressed to either severe or profound loss, hearing returned to baseline levels during the succeeding months.
Audiometry, long term. All 22 pat ients underwent follow-up audiometry at various times. Long-term hearing impro vement was identified in 2 patients (9. 1%; patients 2 and 3); 1 of these patients had received 3 perfusions of 80 mg/ml ofmethylprednisolone and the other had received 5 perfusions of I0 mg/ml ofdexa methaso ne (table I) . Based on PTA, long-term hear ing declined by at least 10 dB in 9 patient s (40.9%); 4 of these patients had received intratym pan ic perfusion of gentamicin in addition to a steroi d. Of these 9 patients, hearing loss progressed from mild to moderate in 3, from mild to severe in 3, from moderate to seve re in 2, and from moderate to profound in 1. In summary, 3 of the 9 patients had a moderate hearing loss, 5 had a severe loss, and I had a profo und loss. Nota bly, the patient who had progressed to profound hearing loss had received intratymp anic gentamicin.
With respect to long-term changes in SDS, 1 patient (4.5 %) had an increase of at least 15% and 6 (27.3%) had a decrease (table 2) .
Assessment of long-term lOW-frequency PTA revealed an improvement ofat least 10 dB in 4 patients ( 18.2%) and a deterioration in 8 (36.4%) (table 3). Of these 8 patients, hearing loss progressed from mild to moderate in 2, from mild to severe in 2, from moderate to severe in 1, and from moderate to profound in 1; hearing declined within the moderate category in 2 patients.Thus, in the long term, 4 of the 8 patients had a moderate low-frequency hearing loss, 3 patient s had a severe loss, and 1 had a profound loss. Five of the 8 patie nts had receive d intratympanic gentamicin.
A dditional treatments. Overall, 10 patients (45.5%) had sought one or more esca lating treatments for Meniere's disease; 6 rece ived intratymp anic gentamicin, 6 received oral methotrexate, and 1underwent vestibularnerve section. Ofnote, both patie nts whose long-term PTAhad improved by at least 10 dB went on to seek additional treatment for intractable vertigo; I received methotr exate and I received both methotrexate and intratympanic gentamicin.
Complications. No tympanic membrane or middle ear complication was identified in any patient.
Discussion
Intratymp anic steroid perfusion is a minimally invasive, nonde stru ctive treatment for Meniere 's disease that is associated with a low rate of complications. The results of intratym panic stero id perfusion reported in the literatur e have been mixed:
• !toh and Sakata studie d the effec ts of intratympanic . dexamethaso ne and intratympanic lidocaine on vertigo and tinnitus in 136 patients with Men iere's disease.'?They found that the success rates of the steroi d were 80% with r-spect to vertigo and 74% with respect to tinnitus.
• Silverstei n et al investigated the effects of intratympanic dexa methasone and methylprednisolone on various subtypes of inner ear disease and tinnitus.' They found an initial benefit in 47% of patie nts, 60% of whom had Men iere 's disease. This benefit waned slightly dur ing a mean follow-u p of 4.5 months.
• In a prospective review, Barrs et al achieved comp lete con trol of vertigo in II of2 1 patients (52.4%) at 3 months and in 9 (42.9%) at 6 month s." However, they observe d no change ill hear ing.
• Ham id, in :) study of 60 patients ove r a 24-month pe-386 riod, demonstrated a 90% success rate in vertigo control and hearing improve ment using a protocol that included 24 mg/m l of dexamethasone." • In the only prospective, randomized, doubl e-blind , crossover study of intratympanic perfusion in Meniere 's disease, Silvers tein et al did not demonstrate any significant changes in hearing, tinnitus, caloric vestibu lar responses, or patients ' subjective assessments of symptoms over a 6-week study perio d. "
• In a retrospe ctive review,Arriaga and Goldman focused on short-term hearing following a single application of intratympanic dexa methasone in Gelfoam. r'They fou nd that only 6 of 19 patie nts (3 1.6%) experienced improvement.
As evidenced by these reports , research has not ju stified the initial enthusiasm for intratymp anic stero id perfusion as a definitive therapy for active Meniere's disease. The variations in success rates may reflect the episodic natural history of Meniere's disease as well as the inclusion of patients with different stages of disease.IS Our study had inherent limitations, including its retrospective nature, other confounding treatments, and the fact that different brands and conce ntrations of stero ids were used. With respec t to the latter limitation, the 24-mg/ml concen tration ofdexamethasone had been disco ntinued by its manufacturer during the study period, which meant that only those patients who had been treated during the earlier portion of the study were perfused with this concentration . Moreover, a trend toward greater use ofmethylprednisolone had been influenced by a report on steroid pharmacokinetics by Parnes et al in 1999. 7 The results of our study are similar to those of Barrs et ai, who reported vertigo contro l during the immediate postperfusion period in many of their patients.I I Also, short-term improvement in hearing was not identified in either study.
Our study did not revea l any long-term benefits in either hearing or vertigo contro l. In fact, almost half of our Volume 83, Number 6 patients experienced a decline in hearing. Whether this findin g reflects the natural history of Meniere's disease or is a manifes tation of steroid perfusion or other treatments is subject to debate. The 1 patient in our study who progresse d to long-term profound hearing loss had received intratymp anic gentamicin following steroi d perfusion.
The findings of our study sugges t that steroid perfusion does not alter the course of Meniere's disease, although it may allevia te vertigo during the immediate postperfusion period.Therefore, steroid perfusion may be useful for treating acute exacerbations ofMeniere's disease characterized by promi nent vertigi nous symptoms , especia lly in patients who cannot tolerate oral corticosteroi ds, such as diabetics. Furthermore, the perfusion of a stero id might also serve as a useful diagnostic test to dete rmi ne which patients might respo nd to immun ologic treatm ent. Prospective controlled studies are warra nted to determine the validity of this treatment. For now, definitive therapy lies in other modalities of treatment. 
